Form 4: Predictive Oncology Inc. Director Acquires Shares
SEC Form 4 Filing
Gregory St. Clair Sr., a director of Predictive Oncology Inc., acquired 3,268 shares of common stock on April 5, 2024.
Summary
- On April 5, 2024, Gregory St. Clair Sr., a director of Predictive Oncology Inc., acquired 3,268 shares of common stock.
- The acquisition was a direct transaction.
- Following the transaction, St. Clair's beneficial ownership in Predictive Oncology Inc. increased to 22,534 shares.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of a director's stock purchase, which can be interpreted as a slightly positive signal, but it's not a major event.
Positives
- A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
This is a standard disclosure of insider trading activity, which is common in the biotechnology industry. Monitoring insider transactions can provide insights into management's sentiment about the company's prospects.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 04/05/2024 | Date of transaction: Gregory St. Clair Sr. acquired shares of common stock. |
| 04/12/2024 | Date of signature on the SEC Form 4. |
Keywords
Predictive Oncology Inc., POAI, Gregory St. Clair Sr., Director, Stock Acquisition, Beneficial Ownership, SEC Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.